series-b
Stage
4
Investors
About
NeRRe Therapeutics is a clinical-stage biotechnology company focused on developing neurokinin-1 receptor antagonists for the treatment of conditions caused by neuronal hypersensitivity, primarily targeting respiratory conditions such as chronic cough associated with idiopathic pulmonary fibrosis.
Explore NeRRe Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.